secwatch.observer — SEC 8-K summary
======================================

Issuer:     FRACTYL HEALTH, INC. (GUTS)
CIK:        0001572616
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0001193125-24-082586
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fractyl Health Receives FDA IDE Approval for Revita Pivotal Study in Weight Maintenance
--------------------------------------------------------------------------------

- FDA approved Investigational Device Exemption for Revita Remain-1 pivotal study for weight maintenance after GLP-1RA discontinuation.
- Remain-1 is a randomized, double-blind trial vs sham in patients who lost ≥15% body weight on tirzepatide; at least 315 subjects randomized 2:1.
- Fractyl Health will also run Reveal-1 open-label cohort and provide updates in the second half of 2024.
- Revita is an outpatient endoscopic procedure targeting duodenum aimed at durable weight loss without ongoing medical therapy.
- CEO Harith Rajagopalan and Dr. Christopher Thompson highlighted the unmet need for durable weight maintenance solutions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1572616/000119312524082586/0001193125-24-082586-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1572616/000119312524082586/d807199d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-082586

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer